Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Miller Receives Biomaterials Award for Celiac Disease Nanoparticle Therapy
Campus News

Miller Receives Biomaterials Award for Celiac Disease Nanoparticle Therapy

By Will DossApr 12, 2021
Share
Facebook Twitter Email
Stephen Miller, PhD, the Judy Gugenheim Research Professor of Microbiology-Immunology, received the 2021 Technology Innovation and Development Award from the Society For Biomaterials (SFB).

Stephen Miller, PhD, the Judy Gugenheim Research Professor of Microbiology-Immunology, has received the 2021 Technology Innovation and Development Award from the Society For Biomaterials (SFB).

Miller is among a group of scientists who designed and tested nanoparticles that induce gluten tolerance in celiac disease, findings that were published in the journal Gastroenterology.

“The study is the first demonstration that immune tolerance to gluten can be induced in humans with celiac using a ‘negative vaccine’ consisting of gluten encapsulated within nanoparticles which induces a regulatory immune response,” said Miller, who is also a professor of Dermatology, of Medicine in the Division of Gastroenterology and Hepatology and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

About 1 percent of the population has celiac disease, a serious autoimmune disease in which the ingestion of gluten leads to damage in the small intestine. When people with celiac disease eat gluten — a protein found in wheat — their body mounts an immune response that attacks the small intestine.

Miller and his colleagues designed a biodegradable nanoparticle containing gluten that teaches the immune system that gluten is safe. The nanoparticle acts like a Trojan horse, hiding the allergen in a friendly shell to convince the immune system not to attack it.

After treatment with the technology, patients in the trial were able to eat gluten with a substantial reduction in inflammation, while patients in the untreated control group developed inflammation in the small intestine that is a characteristic of celiac disease.

Currently, there is no treatment for celiac disease, and doctors can only recommend gluten avoidance. This nanoparticle platform could be the key to a long-awaited treatment, not just for celiac disease but for other autoimmune and allergic diseases as well, according to Miller.

“Traditional treatments for autoimmune disease employ immunosuppressive drugs which lack specificity and make patients highly susceptible to infections and increase rates of cancer,” Miller said. “The clinical trial proved that the gluten-containing nanoparticles were safe and highly efficacious.”

The study was sponsored by COUR Pharmaceuticals Development and supported by Takeda Pharmaceuticals International.

The SFB is a multidisciplinary society of academic, healthcare, governmental and business professionals dedicated to promoting advancements in all aspects of biomaterial science, education and professional standards to enhance human health and quality of life.

Awards Faculty Gastroenterology Immunology Research
Share. Facebook Twitter Email

Related Posts

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Calcium Channel Blockers May Improve Chemotherapy Response

Jun 21, 2022

Comments are closed.

Latest News

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022

Calcium Channel Blockers May Improve Chemotherapy Response

Jun 21, 2022

Expanded Role for Calcium Channels in T-Cells

Jun 17, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220607_Feinberg Campus_0070
20220607_Feinberg Campus_0066
20220607_Feinberg Campus_0054
Northwestern University 2022. Photo by Jim Prisching
20220607_Feinberg Campus_0077
20220607_Feinberg Campus_0063
20220607_Feinberg Campus_0111
20220607_Feinberg Campus_0083
20220607_Feinberg Campus_0018
20220607_Feinberg Campus_0023
20220607_Feinberg Campus_0072 (2)
20220607_Feinberg Campus_0120

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.